Insider Selling: Cadrenal Therapeutics (NASDAQ:CVKD) CEO Sells 2,989 Shares of Stock

Posted by Stanley Muller on May 29th, 2026

Cadrenal Therapeutics, Inc. (NASDAQ:CVKD – Get Free Report) CEO Quang Pham sold 2,989 shares of the firm’s stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $4.93, for a total transaction of $14,735.77. Following the sale, the chief executive officer directly owned 182,161 shares in the company, valued at approximately $898,053.73. The trade was a 1.61% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Cadrenal Therapeutics Stock Down 1.8%

Shares of NASDAQ CVKD traded down $0.09 during trading on Friday, reaching $4.91. 28,017 shares of the company traded hands, compared to its average volume of 54,242. The firm has a 50 day simple moving average of $5.35 and a 200-day simple moving average of $7.20. The stock has a market capitalization of $14.09 million, a PE ratio of -0.87 and a beta of 1.81. Cadrenal Therapeutics, Inc. has a 52-week low of $4.21 and a 52-week high of $15.99.

Cadrenal Therapeutics (NASDAQ:CVKD – Get Free Report) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($1.04) earnings per share for the quarter, topping the consensus estimate of ($1.51) by $0.47. As a group, research analysts predict that Cadrenal Therapeutics, Inc. will post -5.52 EPS for the current year.

Institutional Investors Weigh In On Cadrenal Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. DRW Securities LLC bought a new stake in Cadrenal Therapeutics during the 4th quarter worth approximately $171,000. Citadel Advisors LLC bought a new stake in Cadrenal Therapeutics during the 3rd quarter worth approximately $274,000. Geode Capital Management LLC raised its stake in Cadrenal Therapeutics by 14.3% during the 4th quarter. Geode Capital Management LLC now owns 14,528 shares of the company’s stock worth $98,000 after acquiring an additional 1,818 shares during the period. Finally, JPMorgan Chase & Co. bought a new stake in Cadrenal Therapeutics during the 3rd quarter worth approximately $103,000. Institutional investors own 7.92% of the company’s stock.

Wall Street Analysts Forecast Growth

CVKD has been the topic of several recent research reports. HC Wainwright lowered their price objective on shares of Cadrenal Therapeutics from $32.00 to $13.00 and set a “buy” rating on the stock in a research note on Tuesday, April 7th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Cadrenal Therapeutics in a research note on Monday, April 20th. Finally, Wall Street Zen upgraded shares of Cadrenal Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 9th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Cadrenal Therapeutics currently has an average rating of “Hold” and a consensus price target of $13.00.

View Our Latest Report on Cadrenal Therapeutics

Cadrenal Therapeutics Company Profile

(Get Free Report)

Cadrenal Therapeutics, Inc operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.